Search for drugs:
Typing the drug name to query
AZILSARTAN KAMEDOXOMIL
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- Effect on Cardiac Repolarization
- A thorough QT/QTc study was conducted to assess the potential of azilsartan to prolong the QT/QTc interval in healthy subjects. There was no evidence of QT/QTc prolongation at a dose of 320 mg of Edarbi.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
0
24092
Other ADRs
2752
38378835
Odds Ratio = 0.0
Drug Property Information
ATC Code(s):
- C09CA09 - azilsartan kamedoxomil
- C09CA - "Angiotensin II antagonists, plain"
- C09C - "ANGIOTENSIN II ANTAGONISTS, PLAIN"
- C09 - AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
- C - CARDIOVASCULAR SYSTEM
Active Ingredient:Azilsartan kamedoxomil
Active Ingredient UNII:WEC6I2K1FC
Drugbank ID:DB08822
PubChem Compound:11238823
CAS Number:863031-21-4
Dosage Form(s):tablet
Route(s) Of Administrator:oral
Daily Dose:
- 40.0 mg/day C09CA09
Chemical Structure: 
SMILE Code:
CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NOC(=O)N1)C(=CC=C2)C(=O)OCC1=C(C)OC(=O)O1
CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NOC(=O)N1)C(=CC=C2)C(=O)OCC1=C(C)OC(=O)O1
Reference
N/A
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.